Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT ...

Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other cheap ...

The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 billion, ...

Priovant Therapeutics, a company established in 2021 as part of a transaction between Pfizer (PFE) and Roivant Sciences (ROIV ...

Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share. The trade increased direct holdings ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best mid ...

The Roivant Sciences subsidiary Priovant Therapeutics has announced positive results from the Phase II BEACON study of brepocitinib in cutaneous sarcoidosis (CS).

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment analysis.

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...